GlassScriptPhysician profile
Victoria Grey
NPI 1538405238
$2,751.70
in general payments reported to CMS, 2019-2025
23 companies · $32.27 in 2025
The $32.27 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $1,587 · 2023: $991 · 2025: $32.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948 · Education: $75.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $948.32 |
| Education | $75.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $480.96 | 2022-2023 | Fasenra, Breztri, Airsupra |
| Jazz Pharmaceuticals INC. | $418.49 | 2022-2023 | |
| Harmony Biosciences LLC | $361.55 | 2021-2022 | |
| Mylan Specialty L.P. | $238.68 | 2022-2023 | Yupelri |
| Genzyme Corporation | $156.55 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $155.93 | 2022-2023 | Quviviq |
| Glaxosmithkline, LLC. | $148.41 | 2022-2023 | Trelegy Ellipta, Arexvy, Nucala |
| Janssen Pharmaceuticals, INC | $111.12 | 2022 | |
| Grifols USA, LLC | $87.00 | 2022-2023 | Prolastin-C Liquid |
| Philips North America LLC | $81.82 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.81 | 2022-2023 | Spiriva Respimat, Ofev |
| Abbvie INC. | $75.06 | 2022-2023 | |
| Actelion Pharmaceuticals US, INC. | $66.16 | 2022-2023 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $54.58 | 2021-2022 | |
| Novo Nordisk INC | $45.07 | 2023-2025 | Wegovy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $38.95 | 2022 | |
| Paratek Pharmaceuticals, INC. | $36.60 | 2023 | Nuzyra |
| Boston Scientific Corporation | $24.85 | 2023 | |
| Axsome Therapeutics, INC. | $23.49 | 2023 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $21.36 | 2022 | |
| Amgen INC. | $17.54 | 2022 | |
| Merck Sharp & Dohme LLC | $15.06 | 2023 | |
| Gilead Sciences, INC. | $13.66 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Grey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.